Vesalius Therapeutics
Cambridge, US · 2 known investors
Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
YA
Yasir Al-WakeelCEO
Investors · 2
In the news
- Sell or Invest in Vesalius Therapeutics Stock Pre-IPOnasdaqprivatemarket.com · 2025
- Vesalius Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2023
- Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch | BioPharma Divebiopharmadive.com · 2022
- Vesalius Therapeutics lands $75mventurecapitaljournal.com · 2022
- Flagship unveils Vesalius with $75M to bankroll ambitious target of treating 90% of human illnesses | Fierce Biotechfiercebiotech.com · 2022